EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSMOCG00000004288
Gene Symbol: CACNA1C
3 Cross references
211 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSMOCG00000015213
Gene Symbol: CACNA1D
3 Cross references
281 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSMOCG00000019081
Gene Symbol: CACNA1E
3 Cross references
294 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSMOCG00000006187
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSMOCG00000018501
Gene Symbol: CACNA1H
3 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSMOCG00000015926
Gene Symbol: CACNA1I
3 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSMOCG00000022841
Gene Symbol: CACNA1S
3 Cross references
259 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSMOCG00000021705
Gene Symbol: CNR1
3 Cross references
205 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSMOCG00000007690
Gene Symbol: CNR2
3 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSMOCG00000000956
Gene Symbol: CA1
3 Cross references
285 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSMOCG00000011104
Gene Symbol: CA12
3 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSMOCG00000021098
Gene Symbol: CA13
3 Cross references
288 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).